Skip to content
value.today
Biozone Pharmaceuticals, Inc. logo

Biozone Pharmaceuticals, Inc.

Formerly International Surf Resorts Inc.

Biozone Pharmaceuticals, Inc. is listed today as Cocrystal Pharma, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 6 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Biozone Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2017$3 MPrivate placement after listing$2 to $10 million

Biozone Pharmaceuticals, Inc.: Private sale, Apr 2017

Investors in this round

3 investors had bought by the notice of May 2, 2017: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Biozone Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary Wilcox · Executive Officer, Director
  • James F. Martin · Executive Officer
  • Sam F. Lee · Executive Officer
  • David S. Block · Director
  • Jane H. Hsiao · Director
  • Phillip S. Frost · Director
  • Raymond F. Schinazi · Director
  • Steven D. Rubin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gary Wilcox, Interim Chief Executive Officer. Source: SEC Form D, newest notice filed May 2, 2017. Read the notice at the SEC.

equitySEC
Sep 2016$4 MPrivate placement after listing$2 to $10 million

Biozone Pharmaceuticals, Inc.: Private sale, Sep 2016

Investors in this round

4 investors had bought by the notice of Sep 15, 2016: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Biozone Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Curtis F. Dale · Executive Officer
  • Gary Wilcox · Executive Officer, Director
  • Sam F. Lee · Executive Officer
  • Walt Addison Linscott · Executive Officer
  • David S. Block · Director
  • Jane H. Hsiao · Director
  • Phillip S. Frost · Director
  • Raymond F. Schinazi · Director
  • Steven D. Rubin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gary Wilcox, Interim Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 15, 2016. Read the notice at the SEC.

equitySEC
Mar 2016$5 MPrivate placement after listing$2 to $10 million

Biozone Pharmaceuticals, Inc.: Private sale, Mar 2016

Investors in this round

12 investors had bought by the notice of Mar 30, 2016: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Biozone Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Curtis A Dale · Executive Officer
  • Douglas L Mayers · Executive Officer
  • Jeffrey A Meckler · Executive Officer, Director
  • Sam A Lee · Executive Officer
  • Walt Addison Linscott · Executive Officer
  • David S Block · Director
  • Gary A Wilcox · Director
  • Jane H Hsiao · Director
  • Phillip A Frost · Director
  • Raymond F Schinazi · Director
  • Steven D Rubin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Meckler, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 30, 2016. Read the notice at the SEC.

equitySEC
Jan 2014$3 MPrivate placement after listing$2 to $10 million

Biozone Pharmaceuticals, Inc.: Private sale, Jan 2014

Investors in this round

8 investors had bought by the notice of Jan 31, 2014: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Biozone Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$125,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Gary Wilcox · Executive Officer, Director
  • Gerald McGuire · Executive Officer
  • Sam Lee · Executive Officer, Director
  • Jane Hsiao · Director
  • Phillip Frost · Director
  • Roger Kornberg · Director
  • Steven Rubin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Palladium Capital Advisors, LLC · New York, New YorkSold in FL, ID, IL, NY, TX

Signed by Gary Wilcox, Ceo. Source: SEC Form D, newest notice filed Jan 31, 2014. Read the notice at the SEC.

equity, optionsSEC
Oct 2013$4 MPrivate placement after listing$2 to $10 million

Biozone Pharmaceuticals, Inc.: Private sale, Oct 2013

Investors in this round

22 investors had bought by the notice of Nov 5, 2013: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Biozone Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$50,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Brian M. Keller · Executive Officer, Director
  • Elliot M. Maza · Executive Officer, Director
  • Roberto M. Prego-Novo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Palladium Capital Advisors, LLC · New York, New YorkSold in CA, FL, ID, NJ, NY, TX

Remarks in the notice

  • On fees: “In addition to the $50,000, Palladium Capital Advisors LLC also received 100,000 shares of common stock and 100,000 10-year warrants”

Signed by Elliot Maza, Ceo. Source: SEC Form D, newest notice filed Nov 5, 2013. Read the notice at the SEC.

equity, optionsSEC
Aug 2013$2 MPrivate placement after listing$2 to $10 million

Biozone Pharmaceuticals, Inc.: Private sale, Aug 2013

Investors in this round

1 investor had bought by the notice of Sep 5, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Biozone Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Brian M. Keller · Executive Officer, Director · President and Chief Scientific Officer
  • Christian M. Oertle · Executive Officer · Chief Strategy Officer
  • Elliot M. Maza · Executive Officer, Director · Chief Executive Officer, Chief Financial Officer and Secretary
  • Roberto M. Prego-Novo · Director · Chairman

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Elliot Maza, Ceo. Source: SEC Form D, newest notice filed Sep 5, 2013. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Biozone Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (May 2017).

    SEC Form D · May 2017

  • The industry group it chose in its notices: Other.

    SEC Form D · May 2017

That is all the official record says: Biozone Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Biozone Pharmaceuticals, Inc. are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Biozone Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Frost Gamma Investments TrustFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Gary WilcoxPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2014)SEC Form 3
Opko Health, Inc.Companynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Roger D. KornbergPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2014)SEC Form 3
Sam LeePersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2014)SEC Form 3
Steven D. RubinPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Cocrystal Pharma, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Biozone Pharmaceuticals, Inc.
NameRoleNamed in
Gary WilcoxExecutive officerMay 2017
James F. MartinExecutive officerMay 2017
Sam F. LeeExecutive officerMay 2017
Curtis F. DaleExecutive officerSep 2016
Walt Addison LinscottExecutive officerSep 2016
Curtis A DaleExecutive officerMar 2016
Douglas L MayersExecutive officerMar 2016
Jeffrey A MecklerExecutive officerMar 2016
Sam A LeeExecutive officerMar 2016
Gerald McGuireExecutive officerJan 2014
Sam LeeExecutive officerJan 2014
Brian M. KellerExecutive officerNov 2013
Elliot M. MazaExecutive officerNov 2013
Christian M. OertleChief Strategy OfficerSep 2013
David S. BlockDirectorMay 2017
Gary WilcoxDirectorMay 2017
Jane H. HsiaoDirectorMay 2017
Phillip S. FrostDirectorMay 2017
Raymond F. SchinaziDirectorMay 2017
Steven D. RubinDirectorMay 2017
David S BlockDirectorMar 2016
Gary A WilcoxDirectorMar 2016
Jane H HsiaoDirectorMar 2016
Jeffrey A MecklerDirectorMar 2016
Phillip A FrostDirectorMar 2016
Raymond F SchinaziDirectorMar 2016
Steven D RubinDirectorMar 2016
Jane HsiaoDirectorJan 2014
Phillip FrostDirectorJan 2014
Roger KornbergDirectorJan 2014
Sam LeeDirectorJan 2014
Steven RubinDirectorJan 2014
Brian M. KellerDirectorNov 2013
Elliot M. MazaDirectorNov 2013
Roberto M. Prego-NovoDirectorNov 2013

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.